Section Arrow
Quote
FDMT.NASDAQ
- 4D Molecular Therapeutics
Quotes are at least 15-min delayed:2024/05/21 03:10 EDT
Last
 26
+0.66 (+2.60%)
Day High 
26.25 
Prev. Close
25.34 
1-M High
27.84 
Volume 
462.61K 
Bid
24.41
Ask
26
Day Low
25.02 
Open
25.33 
1-M Low
22.75 
Market Cap 
1.31B 
Currency USD 
P/E -- 
%Yield 0 
10-SMA 25.91 
20-SMA 25.38 
50-SMA 27.82 
52-W High 36.25 
52-W Low 9.44 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.36/-3.73
Enterprise Value
1.32B
Balance Sheet
Book Value Per Share
11.62
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
20.72M
Operating Revenue Per Share
0.04
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
SCPXScorpius Holdings0.16+0.0565+54.59%-- 
NBYNovaBay Pharmaceuticals0.1744+0.0558+47.05%-- 
GTBPGT Biopharma7.8+4.68+150.00%-- 
JAGXJaguar Health0.1686-0.0899-34.78%0.48PE
KTRAKintara Therapeutics0.175+0.032+22.38%-- 
Quotes are at least 15-min delayed：2024/05/21 03:10 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.